Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals (Nasdaq: RYTM) has granted inducement restricted stock units (RSUs) to three new employees, totaling 15,750 shares of common stock. The grants were approved on November 7, 2024, under the company's 2022 Employment Inducement Plan. The RSUs will vest over four years, with 25% vesting annually on each hire date anniversary, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are specifically designed as employment inducements.
Rhythm Pharmaceuticals (RYTM), a global commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced its participation in two upcoming investor conferences. David Meeker, Chair, President and CEO, will participate in fireside chats at the Guggenheim Securities Healthcare Innovation Conference on November 11 and the Stifel 2024 Healthcare Conference on November 18, both at 11:30 a.m. ET. The presentations will be webcasted and available on the company's website under the Investor Relations section, with replays accessible for 30 days.
Rhythm Pharmaceuticals (RYTM) reported Q3 2024 global sales of IMCIVREE® at $33.3 million, up 14% from Q2 2024. Early-access program data showed adult patients with acquired hypothalamic obesity achieved 12.8% mean BMI reduction after three months. The FDA accepted sNDA for Priority Review to expand IMCIVREE label for patients as young as 2 years, with PDUFA date of Dec. 26, 2024. Q3 net loss was $45.0 million ($0.73 per share). The company has $298.4 million cash on hand, expected to support operations into 2026.
Rhythm Pharmaceuticals (RYTM) presented five new data sets at ObesityWeek® 2024, showcasing positive results for setmelanotide therapy across multiple studies. Real-world data showed a mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity after three months, extending to 21.3% at six months. The Phase 2 DAYBREAK trial demonstrated a 12.4% mean BMI reduction in patients with rare MC4R pathway diseases after 40 weeks. Notable results included a 23.8% BMI reduction in pediatric patients aged 2-6 years with BBS or POMC/LEPR Deficiency at 18 months. Analysis of 43,000 genetic samples revealed associations between genetic variants and early-onset obesity.
Rhythm Pharmaceuticals (RYTM) and Axovia Therapeutics announced a joint research collaboration to advance the understanding of Bardet-Biedl syndrome (BBS). The partnership combines Rhythm's expertise in melanocortin-4 receptor pathway research and their commercially available drug for treating hyperphagia and severe obesity in BBS patients with Axovia's focus on gene therapy addressing loss of sight and obesity in BBS patients. The collaboration aims to pool knowledge from their respective screening efforts to improve patient care.
Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, has announced new employment inducement grants. On October 4, 2024, the company's Compensation & Management Development Committee granted inducement restricted stock units (RSUs) covering 30,050 shares of common stock to nine new employees.
These RSUs are subject to the Rhythm Pharmaceuticals 2022 Employment Inducement Plan, which is used exclusively for granting equity awards to new employees as per Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the hire date, contingent on continued employment.
Rhythm Pharmaceuticals (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, has announced new employment inducement grants. On September 11, 2024, the company's Compensation & Management Development Committee granted inducement restricted stock units (RSUs) covering 15,450 shares of common stock to four new employees.
These RSUs are subject to the terms of Rhythm's 2022 Employment Inducement Plan, adopted on February 9, 2022, and used exclusively for equity awards to new employees as per Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually on the hire date anniversary, contingent on continued employment.
Rhythm Pharmaceuticals announced that the FDA has accepted their supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) with Priority Review. The sNDA aims to expand the label to treat obesity due to Bardet-Biedl syndrome (BBS) or POMC/LEPR deficiency in children as young as 2 years old. The FDA set a PDUFA goal date of December 26, 2024.
The sNDA is based on data from a Phase 3 trial in patients aged 2 to 6 years. Results showed a 3.04 mean reduction in BMI-Z score and 18.4% mean reduction in BMI. In July 2024, the European Commission expanded IMCIVREE's marketing authorization for children as young as 2 years old with these conditions.
Rhythm Pharmaceuticals (Nasdaq: RYTM), a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The event will take place at Encore Boston Harbor on Thursday, September 5, 2024.
Dr. David Meeker, Chair, President and CEO of Rhythm Pharmaceuticals, will engage in a fireside chat at 3:45 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the company's website at www.rhythmtx.com under the 'Events & Presentations' section of the Investor Relations page. A replay of the webcast will be available for 30 days following the presentation.
Rhythm Pharmaceuticals (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, has announced new employment inducement grants. On August 8, 2024, the company's Compensation & Management Development Committee granted inducement restricted stock units (RSUs) covering 16,200 shares of common stock to five new employees. These RSUs are part of the Rhythm Pharmaceuticals 2022 Employment Inducement Plan, adopted on February 9, 2022, and are used exclusively for equity awards to new hires as per Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on each employment anniversary, contingent on continued employment.